Evidence map›Paper›PMID 35718820›Full record

ArticleJournal of neurology2022

Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B).

Pia S Sperber, Pimrapat Gebert, Leonie H A Broersen, Shufan Huo, Sophie K Piper, Bianca Teegen, Peter U Heuschmann, Harald Prüss, Matthias Endres, Thomas G Liman and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Pia S SperberCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Center for Stroke Research Berlin (CSB), Charitéplatz 1, 10117, Berlin, Germany.ORCID http://orcid.org/0000-0002-9534-2374
Pimrapat GebertCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Institute of Biometry and Clinical Epidemiology, Berlin, Germany.
Leonie H A BroersenCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Center for Stroke Research Berlin (CSB), Charitéplatz 1, 10117, Berlin, Germany.
Shufan HuoCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Center for Stroke Research Berlin (CSB), Charitéplatz 1, 10117, Berlin, Germany.
Sophie K PiperCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Institute of Biometry and Clinical Epidemiology, Berlin, Germany.
Bianca TeegenInstitute of Experimental Immunology, Euroimmun AG, Luebeck, Germany.
Peter U HeuschmannUniversity of Würzburg, Institute of Clinical Epidemiology and Biometry, Würzburg, Germany.
Harald PrüssGerman Center for Neurodegenerative Disease DZNE, Partner Site, Berlin, Germany.
Matthias EndresCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Center for Stroke Research Berlin (CSB), Charitéplatz 1, 10117, Berlin, Germany.
Thomas G Liman *Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Center for Stroke Research Berlin (CSB), Charitéplatz 1, 10117, Berlin, Germany. pia.sperber@charite.de.
Bob Siegerink *Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Center for Stroke Research Berlin (CSB), Charitéplatz 1, 10117, Berlin, Germany.
German Center for Neurodegenerative Diseases · DEHumboldt-Universität zu Berlin · DEMax Delbrück Center · DEEuroimmun Medizinische Labordiagnostika (Germany) · DELeiden University Medical Center · NLUniversity of Würzburg · DE

Funding

Bundesministerium für Bildung und Forschung 01 EO 0801
6 · The paper itself

Abstract

objectiveWe aimed to investigate whether serum anti-N-methyl-D-aspartate-receptor GluN1 (previously NR1) antibody (NMDAR1-abs) seropositivity impacts cognitive function (CF) in the long term following ischemic stroke.

methodsData were used from the PROSpective Cohort with Incident Stroke-Berlin. NMDAR1-abs (IgM/IgA/IgG) were measured with cell-based assays from serum obtained within 7 days after the first-ever stroke. Seropositivity was defined as titers ≥ 1:10, low titers as ≤ 1:100 and high titers as > 1:100. We assessed CF at 1, 2 and 3 years after stroke with the Telephone Interview for Cognitive Status-modified (TICS-m) and used crude and propensity score adjusted inverse probability weighted generalized linear models to estimate the impact of NMDAR1-abs serostatus on TICS-m.

resultsData on NMDAR1-abs (median day of sampling = 4[IQR = 2-5]) were available in 583/621 PROSCIS-B patients (39% female; median NIHSS = 2[IQR = 1-4]; median MMSE = 28[IQR:26-30]), of whom 76(13%) were seropositive (IgM: n = 48/IgA: n = 43/IgG: n = 2). Any NMDAR1-abs seropositivity had no impact on TICS-m compared to seronegative patients (βcrude = 0.69[95%CI = - 0.84 to 2.23]; βadjusted = 0.65[95%CI = - 1.00 to 2.30]). Patients with low titers scored better on TICS-m compared to seronegative patients (βcrude = 2.33[95%CI = 0.76 to 3.91]; βadjusted = 2.47[95%CI = 0.75 to 4.19]); in contrast, patients with high titers scored lower on TICS-m (βcrude =  -2.82[95%CI = - 4.90 to - 0.74], βadjusted = - 2.96[95%CI = - 5.13 to - 0.80]), compared to seronegative patients.

conclusionIn our study, NMDAR1-abs seropositivity did not affect CF over 3 years after a first mild to moderate ischemic stroke. CF differed according to NMDAR1-abs serum titer, with patients with high NMDAR1-abs titers having a less favorable cognitive outcome compared to seronegative patients.

Indexed as

Ischemic StrokeStrokeCognitionFemaleHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MMaleProspective StudiesImmunoglobulin AImmunoglobulin GImmunoglobulin MAntibodiesCognitive dysfunctionEpidemiologyIschemiaStroke

Identifiers

PMID35718820
PMCPMC9468072
OpenAlexW4283119051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.